Les inhibiteurs de la voie Wnt dans un modèle animal d'insuffisance rénale chronique avec calcification vasculaire
|Advisor:||Mac-Way, Kai-Kock Fabrice|
|Abstract:||Chronic kidney disease (CKD) patients suffer from a dysregulation of minerals levels which is associated with abnormal bone remodeling and vascular calcification, a process similar to bone formation in that it implies the trans-differentiation of vascular smooth muscle cells into osteoblast-like cells. A link was reported between decreased bone formation and vascular calcification in CKD, but the cause of this link remains unclear. We have studied the involvement of Wnt pathway inhibitors in this process in a rat model of CKD with vascular calcification induced by a calcium, phosphorus and vitamin D supplement (Ca/P/vitD). CKD+Ca/P/vitD rats presented with vascular calcification, decreased bone turnover, defective mineralization and increased levels of circulating and vascular Wnt inhibitors. The expression by the calcified vessel of sclerostin, a Wnt inhibitor typically produced by osteocytes, suggests that vascular osteoblast-like cells could acquire an osteocytic phenotype as osteoblasts do in bone. Moreover, vascular Wnt inhibitors could have consequences on bone and contribute to the decrease in bone formation and the mineralization defect. The high circulating levels of Wnt inhibitors could also have vascular effects, which is supported by the fact that the Wnt/β-catenin pathway appears to be inhibited in the calcified vessels despite the fact that high levels of Wnt inhibitors were not correlated with a decrease in the severity of vascular calcification. Our results therefore suggest an implication of Wnt pathway inhibitors in the bone-vessels link that is frequently observed in CKD.|
|Document Type:||Mémoire de maîtrise|
|Open Access Date:||13 February 2020|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.